Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
6.65
+0.13 (1.99%)
At close: Jun 12, 2026, 4:00 PM EDT
6.78
+0.13 (1.95%)
After-hours: Jun 12, 2026, 5:15 PM EDT

Relmada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
698354163126125
Market Cap Growth
2794.27%2157.41%-49.39%18.05%-79.01%19.50%
Enterprise Value
463.56261.2-29.22-65.32-122.06-86.8
Last Close Price
6.654.830.521.030.874.51
PB Ratio
3.194.090.440.360.190.60
P/TBV Ratio
1.632.200.440.360.180.38
EV/EBITDA Ratio
--0.350.630.760.69
EV/EBIT Ratio
--0.350.630.760.69
EV/FCF Ratio
--0.561.261.180.94
Net Debt / Equity Ratio
-1.07-1.07-1.26-1.13-1.06-1.02
Net Debt / EBITDA Ratio
3.881.570.540.930.921.69
Net Debt / FCF Ratio
5.472.030.871.871.432.31
Quick Ratio
18.1514.464.367.9011.9414.08
Current Ratio
18.2614.624.458.0012.2614.83
Return on Equity (ROE)
-38.58%-94.05%-132.33%-87.51%-90.07%-80.14%
Return on Assets (ROA)
-36.64%-84.54%-117.03%-82.81%-85.72%-73.62%
Return on Invested Capital (ROIC)
-309454.00%-284992.00%-257730.00%-265903.00%-510540.00%-178394.00%
Return on Capital Employed (ROCE)
-38.93%-96.02%-138.80%-91.86%-92.49%-80.10%
Buyback Yield / Dilution
-77.05%-30.88%-0.21%-1.59%-68.80%-12.56%
Total Shareholder Return
-77.05%-30.88%-0.21%-1.59%-68.80%-12.56%
SEC Filings: 10-K · 10-Q